Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Active not recruiting 5Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Osteosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Renal Insufficiency, Chronic 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1

Interventions

tazemetostat 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Exercise 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Lymphoma, Follicular × Specimen Handling × Clear all
NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

City of Hope Medical Center

Phase 2 Suspended
33 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡